SCHEMBL5515523

SCHEMBL5515523

COC(=O)C=CC(=O)c1ccc(OC)c(OC)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 6/20 0.67
MAPT P10636 6/20 0.65
LMNA P02545 3/20 0.65
MEN1 O00255 4/20 0.62
KMT2A Q03164 4/20 0.62
ATM Q13315 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62
TNFRSF1A P19438 2/20 0.61
ABCB1 P08183 1/20 0.61
ALDH1A1 P00352 2/20 0.59
KDM4E B2RXH2 1/20 0.59
NPC1 O15118 1/20 0.58
USP2 O75604 1/20 0.58
MAPK1 P28482 1/20 0.58
CYP3A4 P08684 2/20 0.58
CYP1A2 P05177 1/20 0.58
CYP2C9 P11712 1/20 0.58
TSHR P16473 1/20 0.58
CYP2C19 P33261 1/20 0.58
CA12 O43570 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5515521 1.00 ABCG2 (0.67) ABCG2MAPTLMNAMEN1KMT2A
SCHEMBL5585560 0.85 ABCG2 (0.69) ABCG2MAPTLMNAMEN1KMT2A
SCHEMBL5585564 0.85 ABCG2 (0.69) ABCG2MAPTLMNAMEN1KMT2A
SCHEMBL5585546 0.85 ABCG2 (0.69) ABCG2MAPTLMNAMEN1KMT2A
SCHEMBL5585542 0.85 ABCG2 (0.69) ABCG2MAPTLMNAMEN1KMT2A
SCHEMBL10540781 0.85 ABCG2 (0.59) ABCG2MAPTLMNAMEN1KMT2A
SCHEMBL5166792 0.84 MAPT (0.62) ABCG2MAPTLMNAMEN1KMT2A
SCHEMBL5166787 0.84 MAPT (0.62) ABCG2MAPTLMNAMEN1KMT2A
SCHEMBL5585582 0.83 TNFRSF1A (0.75) ABCG2MAPTLMNAMEN1KMT2A
SCHEMBL5585584 0.83 TNFRSF1A (0.75) ABCG2MAPTLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238812-B2 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEJI SEIKA KAISHA, LTD. (JP) 2007-07-03 US disclosed
US-20060074074-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA PHARMA CO., LTD. (JP) 2006-04-06 US disclosed
US-7022860-B2 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-04 US disclosed
EP-1026167-B1 TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND ANTIALLERGIC AGENTS MEIJI SEIKA KAISHA (JP) 2003-03-05 EP disclosed
US-20020137739-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA PHARMA CO., LTD. (JP) 2002-09-26 US disclosed
US-6372735-B1 ANTIHISTAMINES MEIJI SEIKA KAISHA, LTD. (JP) 2002-04-16 US disclosed
EP-1026167-A1 TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND ANTIALLERGIC MEIJI SEIKA KAISHA LTD. (JP) 2000-08-09 EP disclosed
US-4483868-A ANTIULCER AGENTS ANTISECRETORY AGENTS ROUSSEL UCLAF (FR) 1984-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074074-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents HRH4, CYP2D6, CYP2B6 ABCG2 49/4885MAPT 3031/4885LMNA 3995/4885
US-20020137739-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents HRH4, CYP3A4, TPH1 ABCG2 38/4885MAPT 3223/4885LMNA 3991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.